

Shinn-Cherng Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9637248/publications.pdf>

Version: 2024-02-01

83
papers

1,355
citations

430442

18
h-index

395343

33
g-index

85
all docs

85
docs citations

85
times ranked

1478
citing authors

#	ARTICLE	IF	CITATIONS
1	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. <i>Cancer Medicine</i> , 2022, 11, 104-116.	1.3	7
2	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. <i>World Journal of Gastroenterology</i> , 2022, 28, 140-153.	1.4	6
3	Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients. <i>Cancers</i> , 2022, 14, 2023.	1.7	3
4	Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 303-310.	0.8	8
5	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype 2 infection after completed treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 334-345.	0.8	3
6	Coagulation-related inflammatory pseudotumor of liver. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 528-530.	0.8	0
7	Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 186-196.	4.5	9
8	Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. <i>PLoS ONE</i> , 2021, 16, e0245479.	1.1	5
9	Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan—the Formosa-Like Group. <i>Journal of Viral Hepatitis</i> , 2021, 28, 719-727.	1.0	5
10	Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 255-260.	0.6	6
11	Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2261-2269.	1.4	2
12	Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. <i>Scientific Reports</i> , 2021, 11, 8554.	1.6	11
13	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Scientific Reports</i> , 2021, 11, 8184.	1.6	17
14	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3239-3246.	1.4	0
15	Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 136-143.	4.5	32
16	Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 151-156.	1.4	6
17	Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 473-481.	1.4	7
18	Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2120-2129.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4945.	1.8	9
20	Cure or curd: Modification of lipid profiles and cardiovascular events after hepatitis C virus eradication. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 920-928.	0.8	20
21	Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 460-466.	0.8	3
22	Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2020, 73, 62-71.	1.8	60
23	Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 750-756.	0.8	2
24	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1886-1892.	1.4	8
25	The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. <i>PLoS ONE</i> , 2020, 15, e0242601.	1.1	5
26	Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 249-255.	1.4	10
27	The acceptability of serum sample storage for hepatitis C viral load analysis in chronic hepatitis C patients. <i>Advances in Digestive Medicine</i> , 2019, 6, 58-61.	0.1	0
28	Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. <i>BMJ Open</i> , 2019, 9, e026703.	0.8	17
29	Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis C. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 277-281.	0.6	5
30	Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virus-infected patients. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 99-104.	0.6	12
31	The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. <i>Medicine (United States)</i> , 2019, 98, e15066.	0.4	8
32	Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. <i>Journal of Infectious Diseases</i> , 2019, 219, 1224-1233.	1.9	15
33	Fulminant Emphysematous Pancreatic Pseudocyst: Infected with Normal Skin Flora. <i>American Journal of Medicine</i> , 2019, 132, e41-e42.	0.6	0
34	The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 14-23.	0.8	6
35	Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 54-62.	0.8	3
36	Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1A infection after liver transplantation: Real-world experience. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 518-526.	0.8	15

#	ARTICLE	IF	CITATIONS
37	Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1108-1114.	1.4	6
38	Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. <i>Hepatology International</i> , 2018, 12, 544-551.	1.9	14
39	Association of hyperuricemia with disease severity in chronic hepatitis C patients. <i>PLoS ONE</i> , 2018, 13, e0207043.	1.1	13
40	The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. <i>Oncotarget</i> , 2018, 9, 21313-21321.	0.8	10
41	Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. <i>Scientific Reports</i> , 2018, 8, 15821.	1.6	6
42	Toll-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. <i>Scientific Reports</i> , 2018, 8, 15058.	1.6	5
43	Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. <i>Oncotarget</i> , 2018, 9, 12240-12249.	0.8	5
44	A real-world impact of cost-effectiveness of pegylated interferon/ribavirin regimens on treatment-naïve chronic hepatitis C patients in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 44-49.	0.8	11
45	Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. <i>EBioMedicine</i> , 2017, 15, 81-89.	2.7	30
46	Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1754-1762.	1.4	59
47	HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. <i>Hepatology International</i> , 2017, 11, 199-208.	1.9	13
48	Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 284-289.	0.8	2
49	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein expression predicts disease severity in chronic hepatitis C patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 394-399.	0.8	9
50	Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 1690-1697.	3.2	32
51	Disease severity and erythropoiesis in chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 864-869.	1.4	4
52	Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. <i>PLoS ONE</i> , 2017, 12, e0178883.	1.1	18
53	The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0184878.	1.1	5
54	Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. <i>Oncotarget</i> , 2017, 8, 43925-43933.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C. <i>Oncotarget</i> , 2017, 8, 32618-32625.	0.8	6
56	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. <i>Scientific Reports</i> , 2016, 6, 22995.	1.6	7
57	The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 362-366.	0.8	22
58	Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. <i>Oncotarget</i> , 2016, 7, 61325-61335.	0.8	7
59	The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1768-1774.	1.4	14
60	Extremely rare cause of obstructive jaundice: Non-neoplastic, noninfectious lymphadenitis. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 442-443.	0.8	0
61	Variable uptake feature of focal nodular hyperplasia in Tc ^{99m} phytate hepatic scintigraphy/single-photon emission computed tomography: A parametric analysis. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 621-625.	0.8	2
62	Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 77-82.	0.8	11
63	Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2015, 62, 512-518.	1.8	30
64	PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. <i>Scientific Reports</i> , 2015, 5, 11901.	1.6	9
65	Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 271-277.	0.8	3
66	Feasibility and efficacy of helical tomotherapy in cirrhotic patients with unresectable hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2015, 13, 201.	0.8	8
67	Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2015, 10, e0122259.	1.1	16
68	Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2014, 61, 67-74.	1.8	110
69	Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. <i>Antiviral Research</i> , 2014, 105, 135-142.	1.9	16
70	Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. <i>Hepatology International</i> , 2013, 7, 162-170.	1.9	4
71	The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. <i>Hepatology International</i> , 2013, 7, 180-187.	1.9	2
72	Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. <i>Antiviral Research</i> , 2012, 93, 239-244.	1.9	44

#	ARTICLE	IF	CITATIONS
73	Outcome of Chronic Hepatitis C Patients who Required Early Termination of Pegylated Interferon- α plus Ribavirin Combination Therapy. <i>Antiviral Therapy</i> , 2006, 11, 1015-1020.	0.6	29
74	Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 636-640.	1.4	56
75	Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. <i>Journal of Medical Virology</i> , 2001, 65, 58-65.	2.5	97
76	Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. , 2001, 65, 58.		1
77	Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 417-421.	1.4	22
78	Clinical Evaluation of the Automated COBAS AMPLICOR HCV MONITOR Test Version 2.0 for Quantifying Serum Hepatitis C Virus RNA and Comparison to the Quantiplex HCV Version 2.0 Test. <i>Journal of Clinical Microbiology</i> , 2000, 38, 2933-2939.	1.8	46
79	The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 33, S124-S127.	1.1	28
80	Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemoembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1994, 9, 1-6.	1.4	16
81	The role of hepatitis C virus in chronic hepatitis B virus infection. <i>Gastroenterologia Japonica</i> , 1993, 28, 23-27.	0.4	33
82	Anti-HCV antibody in Chinese cirrhotic patients with or without hepatocellular carcinoma: Relation to multitransfusion. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1992, 7, 128-131.	1.4	5
83	The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. <i>Cancer</i> , 1992, 69, 2052-2054.	2.0	116